Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 3,101–3,200 of 4,108
Kim, J. J., Jang, E. J., Cho, J. W., & Sohn, H. S. (2019) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2019.29.3.147 · Cited by 1
Cvjetković, Đ., Cvjetković-Nedeljković, S., Martić, N., Sabo, A., Tomić, Z., & Milijašević, B. (2019) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj1903857c · Cited by 1
Bone health assessments by student pharmacists during interprofessional education
Fava, J. P., Whitney, M. E., Mendez, J., et al. (2020) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2020.04.019 · Cited by 1
PROFILE OF OSTEOPOROTIC FRACTURES
Yadav, G., & Rathod, C. L. (2020) · International Journal of Medical and Biomedical Studies · doi:10.32553/ijmbs.v4i9.1446 · Cited by 1
Nigh, E. D., Summers, S. H., Nguyen, D. M., & Conway, S. A. (2021) · The Journal of Hip Surgery · doi:10.1055/s-0040-1722280 · Cited by 1
Femoral Neck Fracture in a Hemodialysis Patient after Liver Transplantation: A Case Report
鎌田, 聡., Kise, N., Kinoshita, K., et al. (2021) · Progress in Rehabilitation Medicine · doi:10.2490/prm.20210003 · Cited by 1
PAKSOY, K. (2021) · Pamukkale Medical Journal · doi:10.31362/patd.786305 · Cited by 1
Birch, J. T., & Bhattacharya, S. B. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107294967.004 · Cited by 1
Male osteoporosis: Recommendations to improve its treatment
Debiais, F. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105250 · Cited by 1
Soytaş, R. B., Avcı, S., Yavuzer, H., Özkök, S., & Döventaş, A. (2021) · Genel Tıp Dergisi · doi:10.15321/geneltipder.2021.300 · Cited by 1
Keikha, F., & Veisian, M. (2021) · Journal of Obstetrics Gynecology and Cancer Research · doi:10.30699/jogcr.6.4.174 · Cited by 2
Bone Health, Fragility and Fractures
Wilson, H., Calcraft, D., Neville, C., Lanham-New, S. A., & Durrant, L. R. (2021) · Perspectives in nursing management and care for older adults · doi:10.1007/978-3-030-63892-4_9 · Cited by 1
Bernateck, M., Heppner, C., Korsten, P., & Siggelkow, H. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-57487-4_22 · Cited by 1
Osteoporosis knowledge, attitudes, and practices among women in Makkah, Saudi Arabia
Almutairi, G., Barniyah, M., Almalki, B., Alturki, Y., Aljuaid, N., Alharbi, L., & Attiah, M. (2022) · Medical Science · doi:10.54905/disssi/v26i121/ms96e2055 · Cited by 1
http://www.turkosteoporozdergisi.org/tr/Anasayfa
... (2012) · Turkish Journal of Osteoporosis · doi:10.4274/tod.63634 · Cited by 1
Study of Vitamin D Receptor Gene Polymorphisms in Egyptian Patients with Primary Osteoporosis
(2015) · Egyptian Journal of Pure and Applied Science · doi:10.21608/ejaps.2015.184786 · Cited by 1
Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease
Wade, K. S., & Quaas, A. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-17798-4_47 · Cited by 1
Fleischer, S. H., Freire, A. K., Brown, K., Creer, A., Eggett, D. L., & Fullmer, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191610363 · Cited by 2
“While peak bone mass is primarily determined by genetics [2], exposure to various important lifestyle factors during adolescence and young adulthood could affect total bone mass accrual and therefore, may influence the risk of osteoporosis later in life [3].”
BackgroundInfluentialShi, L., Xu, X., Xiang, G., & Duan, S. (2022) · Medicine · doi:10.1097/md.0000000000030522 · Cited by 2
“The anti-osteoporosis interventions had to be recommended by the UK National Osteoporosis Guidelines Group[11] or US National Osteoporosis Foundation.”
BackgroundTrabecular bone score value in young men with ankylosing spondylitis
Kolpakov, K. I., Letyagina, E. A., Omelchenko, V. O., et al. (2022) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2022-460-464 · Cited by 1
Sullivan, D. O., Silke, C., Whelan, B., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01199-2 · Cited by 1
Fuerza muscular como predictora de fragilidad ósea en pacientes con diabetes mellitus tipo 2
Hayón-Ponce, M., García-Fontana, B., Avilés-Pérez, M., González-Salvatierra, S., Moratalla-Aranda, E., & Muñoz-Torres, B. (2021) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2021000400006 · Cited by 5
Deepika, V., Sujatha, B., Saravana Prabha, R., Malathi, S. A. M., & Akila, S. (2022) · International journal of human movement and sports sciences · doi:10.13189/saj.2022.100625 · Cited by 1
Harasym, P., Beaupré, L. A., Juby, A. G., et al. (2023) · Journal of Patient Experience · doi:10.1177/23743735231151537 · Cited by 1
“Individuals with osteoporosis who experience a first fracture have a 20-fold increased risk of a second fracture compared to those individuals with a normal BMD and no prior fracture (3,10,11).”
BackgroundGlucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Rife, E. C., Abdalla, J. E., de la Rocha, J. L., & Emejuaiwe, N. (2023) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-023-01392-5 · Cited by 1
“Evidence of a vertebral or hip fracture on imaging record review [62]”
Multiomics approaches to search for molecular-genetic predictors of osteoporosis
Yalaev, B. I., Tyurin, A. V., & Khusainova, R. I. (2022) · Genes and Cells · doi:10.23868/202205002 · Cited by 1
Prevention and Management of Osteoporosis Through Exercise
Forsyth, J. J., Rounds, A. D., & Zumwalt, M. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-15485-0_17 · Cited by 1
Osteoporosis: A Silent Life Threatening Disease
Roy, K. (2022) · INDIAN JOURNAL OF PHYSIOLOGY AND ALLIED SCIENCES · doi:10.55184/ijpas.v73i1.23 · Cited by 2
Risk of fall and related factors in osteoporosis patients at the National Geriatric Hospital
Anh, T. N., Luc, T. V., Hue, D. T. T., et al. (2023) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v166i5e12.1506 · Cited by 1
Jin, D., Zheng, H., & Yuan, H. (2023) · Bioengineering · doi:10.3390/bioengineering10060716 · Cited by 2
“Bone mineral density (BMD) tests are now internationally recognized as the primary method of diagnosis for vertebral fragility fractures [1,2].”
BackgroundOsteoporosis in adults in clinical practice (1): diagnosis and differential diagnosis
Zikán, V. (2023) · Vnitřní lékařství · doi:10.36290/vnl.2023.052 · Cited by 3
Marcadores de recambio óseo en mujeres postmenopáusicas: utilidad clínica
Marcela Barberán, M., Patricia Díaz, G., Claudio Liberman, G., & Maritza Garrido, P. (2016) · Revista Hospital Clínico Universidad de Chile · doi:10.5354/2735-7996.2016.71118 · Cited by 1
Олегович, К. И., Kabanov, M. Y., Linnik, S. A., et al. (2023) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov209839 · Cited by 1
Jung, M. (2023) · 보건교육·건강증진학회지 · doi:10.14367/kjhep.2023.40.2.93 · Cited by 1
Nutritional considerations for the prevention and treatment of postmenopausal osteoporosis
Grippe, K. M., & Ryan, V. A. (2020) · JAAPA · doi:10.1097/01.jaa.0000977512.83053.bf · Cited by 1
Impact of COVID-19 pandemic on pharmacologic treatment of patients newly diagnosed with osteoporosis
White, M., Hisatomi, L. A., Villegas, A., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291472 · Cited by 1
“Despite guidelines from professional organizations such as the United States Preventive Services Taskforce (USPSTF) and National Osteoporosis Foundation (NOF) recommending screening for and treatment of osteoporosis in at-risk individuals, osteoporosis remains considerably underdiagnosed and undertreated [32, 33].”
BackgroundAmin, S., Barua, O., Monjur, F. M. ;. S., Munajja, T., & Joshi, A. (2023) · Current Research in Public Health · doi:10.31586/crph.2023.768 · Cited by 1
Cosme, I., Nobre, E. L., Travessa, A., dos Santos, C. R., Rocha, J., Lopéz‐Presa, D., & Barbosa, A. P. (2023) · Cureus · doi:10.7759/cureus.47461 · Cited by 1
Vélez-Cuellar, N. N., Toloza-Pérez, Y. G., & Malagón-Rojas, J. (2023) · Salud UIS · doi:10.18273/saluduis.55.e:23071 · Cited by 1
“In addition, bone density decreases 2,15 .”
InfluentialThe implicit reason of secondary osteoporosis: real clinical case
Shutova, A. S., Fedina, E. A., Kuzmin, A. G., et al. (2023) · Obesity and metabolism · doi:10.14341/omet13003 · Cited by 1
Nisa, K. U., Rehman, A. U., & Hani, U. (2023) · Journal of Health and Rehabilitation Research · doi:10.61919/jhrr.v3i2.94 · Cited by 1
Saraiva, F. G., Jonet, J., Roquette, M., et al. (2024) · Cureus · doi:10.7759/cureus.53646 · Cited by 1
“Therefore, children and adults with OI can enhance their overall well-being through a consistent physical activity regimen, incorporating muscle strengthening, aerobic exercise, and recreational activities [16].”
BackgroundInfluentialRibeiro, M. C., de Paula, T. C. S., Monteiro, É. M. H., Evangelista, F. C. C., Gomes, T. F. P., Montezuma, T., & Lucchetta, R. C. (2024) · HU Revista · doi:10.34019/1982-8047.2023.v49.41803
Gera, I., & Szücs, N. (2024) · Fogorvosi Szemle · doi:10.33891/fsz.117.1.11-21 · Cited by 1
Ratnasingam, J., Niyaz, M., Mariyappan, S., Ong, T. I. W., Chan, S. P., Hew, F. L., Yeap, S. S., Velaiutham, S., Thambiah, S. C., & Lekamwasam, S. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01371-w · Cited by 2
İnceoğlu, S. Ç., Ayyildiz, A., Sahin, T., Yilmaz, F., Keskin, K., Dede, B., Cici, F., & Kuran, B. (2024) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.14744/semb.2024.56898 · Cited by 1
., D., Kumar, N., Ronanki, K., & Kant, R. (2022) · Journal of the Uttaranchal Orthopaedic Association · doi:10.4103/juoa.juoa_1_22 · Cited by 1
Closing the Osteoporosis Treatment Gap with Bone Health and Fracture Liaison Services
Sagalla, N., Lee, R., de Souza, T. G., & Colon-Emeric, C. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-56204-4_41 · Cited by 1
Hwang, M., Cheng, D. S., Hah, R. J., & Lantz, J. M. (2023) · JOSPT Cases · doi:10.2519/josptcases.2022.11399 · Cited by 1
Cruz, E. C. E., McMillan, D. W., Reid, K. F., & Valderrábano, R. J. (2024) · Advanced Biology · doi:10.1002/adbi.202400213 · Cited by 1
Total Thyroidectomy: Resection of Two Organs, Not Just One
Ayşan, E. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2145 · Cited by 1
Aman, M. M., Weisbein, J. S., Orhurhu, V., & Phillips, T. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15962-6.00017-5 · Cited by 1
Chlapoutakis, K., Baltas, C. S., Γαλανός, Α., Froudaki, M., & Balanika, A. P. (2024) · PubMed Central · Cited by 1
Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes
Ruggiero, C., Caffarelli, C., Calsolaro, V., Tafaro, L., Riuzzi, F., Bubba, V., Napoli, N., Ferracci, M., Mecocci, P., Giusti, A., et al. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01163-4 · Cited by 1
“Lastly, it is mandatory to obtain information about chronic liver disease, chronic kidney disease, hypercalciuria, anorexia nervosa, chronic obstructive pulmonary disease, rheumatoid arthritis, malignancy, and organ transplantation [57, 58].”
Bridging academia and public interest: the impact of Altmetrics on osteoporosis treatment research
Bulut, Ö. Ö., Alyanak, B., Dede, B. T., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01500-z · Cited by 1
“The “Clinician’s Guide to Prevention and Treatment of Osteoporosis,” authored by Cosman et al. [6], is a seminal work that provides comprehensive guidelines for the prevention and treatment of osteoporosis.”
Sitnikova, N. A., Bondarenko, N. A., & Kushnarenko, A. O. (2025) · Cell and Tissue Biology · doi:10.1134/s1990519x25020117 · Cited by 1
“The main cause of osteoporosis, in addition to aging, is the modern human lifestyle: sedentary lifestyle, monotonous diet, obesity, deficiency of vitamins and microelements, which causes metabolic disorders in the body (Cosman et al., 2014).”
FATORES DE RISCO, DIAGNÓSTICO E ABORDAGENS TERAPÊUTICAS DA OSTEOPOROSE: UMA REVISÃO ATUALIZADA
Oliveira, C. W. D. M., Santos, A. D. S., Saraiva, C. D. V. S., del Corsso, C., de Sousa, M. B. V., Caracas, M. M. T., Carvalho, L. F. L., Handaous, H. R., Barreto, M. D. A., & Menezes, R. A. S. (2025) · Revista Contemporânea · doi:10.56083/rcv5n2-056 · Cited by 23
Selim, C., Çiftçiler, R., Küçükdiler, A. H. E., et al. (2025) · International Journal of Clinical Practice · doi:10.1155/ijcp/5411059 · Cited by 1
“In patients, BMD Z scores for the lumbar spine and hip were categorized accordingly and recorded into two subgroups: osteoporosis or reduced bone mass (Z score < − 2.0) and normal (Z score > − 2.0) [17].”
InfluentialIchikawa, R., Shibata, M., Nakura, Y., Iizuka, K., Uenishi, K., Sekiya, T., Suzuki, A., & Nishizawa, H. (2025) · Nutrients · doi:10.3390/nu17061075 · Cited by 3
“Insufficient calcium (Ca) and vitamin D intake, along with the excessive consumption of alcohol, caffeine, and salt, have been linked to BMD loss [1–3].”
Role of Protein Nutrition for Maintaining the Health of the Musculoskeletal System
Qamar, M. N., Nafees, H., & Feroz, S. A. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-8699-6.ch006 · Cited by 2
Adherence to secondary fracture prevention is associated with reduced risk of subsequent fractures
Bjørnerem, Å., Khoshkhabari, J., Hansen, A. K., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07697-6 · Cited by 1
Bernateck, M., Kuipers, J. G., Zeidler, H. K., Köhler, L., Hülsemann, J. L., & Schnarr, S. (2013) · Springer eBooks · doi:10.1007/978-3-642-37605-4_22 · Cited by 1
Metabolic bone diseases of the spine
Simmons, E. D., Giardino, S. T., & Zheng, Y. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06952-6.00074-9 · Cited by 1
Niveles de vitamina D en mujeres posmenopáusicas con osteoporosis primaria.
Sotelo, W., & Calvo, A. (2011) · Revista Médica Herediana · doi:10.20453/rmh.v22i1.1094 · Cited by 1
Marian, M. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-397155-5.00009-x · Cited by 1
Osteoporosis en los pacientes infectados por el virus de la inmunodeficiencia humana
Gullón, A., & García-Vadillo, A. (2013) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2012.11.001 · Cited by 3
¿Se puede establecer una relación entre los índices FRAX® y QFracturescoresTM?
Gómez, R. S.-O., Castro, A. V., Sanz, A. H., & Arribas, R. M. (2012) · Revista Clínica de Medicina de Familia · doi:10.4321/s1699-695x2012000300004 · Cited by 1
Osteoporosis and Its Risk Factors among Menopausal Women
Khokhar, S., Hasan, J. A., & Qazi, S. (2014) · Cited by 1
Dialysis in the Older Adult: Management of CKD–MBD
Kuhlmann, M. K. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3320-4_10 · Cited by 1
Skeletal Deficits in Type 1 Diabetes Mellitus
Thrailkill, K. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-16402-1_1 · Cited by 1
Ahn, E.-K., Kim, K. S., Park, S.-M., et al. (2015) · Cited by 1
Adewole, O., Giwa, S., Komolafe, O., et al. (2016) · West Indian Medical Journal · doi:10.7727/wimj.2015.374 · Cited by 1
Riznic, N., Milovanovic, D. R., Djukić, A., Јаnkovic, S., Ravanić, D., Ristić, D. I., Petrovic, D., Jovanović, M., Mladenović, V., Zečević, D. R., et al. (2016) · Vojnosanitetski pregled · doi:10.2298/vsp150828084r · Cited by 2
Osteoporosis Overtreatment—A Clinical Problem That Needs to Be Discussed
Xu, F., & Yuan, L. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2731 · Cited by 1
Current Options and Future Directions for Managing Osteoporosis: An update
Oryan, A., & Kamali, A. (2015) · Journal of Sports Medicine & Doping Studies · doi:10.4172/2161-0673.s2-e001 · Cited by 1
Metabolic Bone Disease in Adults with Short Bowel Syndrome
Mack, L. R., & Rochling, F. A. (2016) · CRC Press eBooks · doi:10.1201/b20188-9 · Cited by 1
Jo, M.-J., Jung, K., Kwon, S., Lim, M. J., Park, S., & Park, W. (2016) · Korean Journal of Medicine · doi:10.3904/kjm.2016.91.2.166 · Cited by 1
Management of osteoporosis patients for prosthetic restoration
Baek, J.-Y., Jeon, H.-S., & Lee, J. (2016) · Journal of Dental Rehabilitation and Applied Science · doi:10.14368/jdras.2016.32.2.93 · Cited by 1
Risk Factors for Low Bone Mineral Density in Multiple Sclerosis
Benlidayı, İ. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805298-3.00008-6 · Cited by 3
Five Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive
Sayegh, R. A., & Awwad, J. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-42451-4_2 · Cited by 2
Abdalbary, S. A., & Amr, S. M. (2017) · Modern Applied Science · doi:10.5539/mas.v11n4p65 · Cited by 1
Yılmaz, M., Başbuğ, A., Kaya, A. E., Çağlar, M., Özkara, A., Sungur, M. A., & Ataoğlu, S. (2017) · Konuralp Tıp Dergisi · doi:10.18521/ktd.286409 · Cited by 1
Bone mineral density testing after fragility fracture
Posen, J., Beaton, D., Sale, J. E. M., et al. (2013) · Canadian Family Physician · Cited by 1
Identification of vertebral fractures: a moderately severe solution?
McCloskey, E. V. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4042-z · Cited by 1
Clinical Practice Guidelines for Osteoporosis: Translating Data to Patients?
ORWOLL, E. S. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0957 · Cited by 1
Osteoporosis: Diagnosis, Risk Factors, and Prevention
Sinaki, M., & Pfeifer, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-54016-0_1 · Cited by 1
Positive effects of total and dairy protein intakes on peripheral skeleton bone strength
Xie, D., & Sheng, Z. (2017) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.154450 · Cited by 1
Enhancing Osteoporosis Efforts Through Lifestyle Modifications and Goal-setting Techniques
Prah, A., Richards, E. A., Griggs, R. R., & Simpson, V. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2017.07.015 · Cited by 4
Rehabilitation of Older Patients with Osteo-metabolic Disorders
Iolascon, G., Gimigliano, F., Moretti, A., Covella, E., & Gimigliano, R. (2017) · Practical issues in geriatrics · doi:10.1007/978-3-319-57406-6_27 · Cited by 1
Frequency of Bone Health Presentations at National Hand Meetings
Christensen, D. L., Nappo, K. E., Ficke, B., & Tintle, S. M. (2017) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2017.09.005 · Cited by 1
Osteoporosis: A Clinical Update for Home Healthcare Clinicians
Capriotti, T., & Scanlon, M. (2018) · Home Healthcare Now · doi:10.1097/nhh.0000000000000669 · Cited by 1
Osteoporosis and spine fractures
Brunton, S., Carmichael, B., Gold, D. T., Hull, B., Kauffman, T. L., Koehler, B., Παπαϊωάννου, Α., Rasch, R. F. R., Stracke, H. H. G., & Truumees, E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4588-2.00018-8 · Cited by 1
Public health impact of osteoporosis in older age
Pawłowski, W., Goniewicz, K., Goniewicz, M., et al. (2018) · Journal of Pre-Clinical and Clinical Research · doi:10.26444/jpccr/95244 · Cited by 1
The Chapman Bone Algorithm: A Diagnostic Alternative for the Evaluation of Osteoporosis
Levesque, E., Ketterer, A., Memon, W., et al. (2018) · Chapman University Digital Commons (Chapman University) · Cited by 1
Sobrediagnóstico en la salud de la mujer: el caso de la osteoporosis
Corrochano, E. C., Iglesias, A. P., Navarro, D. F., & Franco, A. (2018) · Atención Primaria · doi:10.1016/j.aprim.2018.07.008 · Cited by 1
Yang, K. C., Wang, S., Lee, J. J., Fann, J. C. ‐., Chiu, S. Y. ‐., Chen, S. L. ‐., Yen, A. M., Chen, H. H., Chen, M. K., & Hung, H. F. (2019) · QJM · doi:10.1093/qjmed/hcz009 · Cited by 1
Impact of bariatric surgery on bone tissue
Martínez, S. B., Jáuregui, E. P., & Martín, J. E. S. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.06.006 · Cited by 2
Evaluation of Serum Vitamin D Levels in Foster's Children Care Center
Amiri, M. (2019) · Journal of Pediatric Health and Nutrition · doi:10.14302/issn.2691-5014.jphn-18-2456 · Cited by 1
Prediction of Osteoporosis Among Vietnamese Women
Tran, D., Rutledge, D. N., & Robertson, S. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.01.017 · Cited by 1
Bischoff-Ferrari, H. A. (2019) · Osteologie/Osteology · doi:10.1055/a-0861-2813 · Cited by 1
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.